CO6300962A2 - Una proteina de fusion que comprende proteina circumesporozoito para uso en una vacuna contra la malaria - Google Patents

Una proteina de fusion que comprende proteina circumesporozoito para uso en una vacuna contra la malaria

Info

Publication number
CO6300962A2
CO6300962A2 CO10071043A CO10071043A CO6300962A2 CO 6300962 A2 CO6300962 A2 CO 6300962A2 CO 10071043 A CO10071043 A CO 10071043A CO 10071043 A CO10071043 A CO 10071043A CO 6300962 A2 CO6300962 A2 CO 6300962A2
Authority
CO
Colombia
Prior art keywords
protein
csv
particle
circumesporozoite
fusion protein
Prior art date
Application number
CO10071043A
Other languages
English (en)
Inventor
Joseph D Cohen
Martine Marchand
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40560235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6300962(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO6300962A2 publication Critical patent/CO6300962A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a una partícula proteínica novedosa, procedimientos para su preparación y purificación, su uso en medicina, en particular en la prevención de infecciones de malaria, composiciones/vacunas que contienen la partícula o anticuerpos contra la partícula proteínica tales como anticuerpos monoclonales o policlonales y su uso, en particular en terapia. Además, pueden prepararse partículas con la proporción específica empleando las levaduras Saccharomyces cerevisiae o Pichia pastoris. Enparticular se refiere a una partícula proteínica inmunógena que comprende los siguientes monómeros: a. una proteína de fusión que comprende secuencias derivadas de una proteína CS de P. vivax y el antígeno S de la hepatitis B (CSV-S), y b. el antígeno S derivado del virus de la hepatitis B,y caracterizada porque la proporción entre S y CSV-S está comprendida en el intervalo de 0,1 a 1. De forma adecuada, la proporción entre S y CSV-S está comprendida en el intervalo de 0,19 a 0,30 o de 0,68 a 0,80.
CO10071043A 2007-12-24 2010-06-11 Una proteina de fusion que comprende proteina circumesporozoito para uso en una vacuna contra la malaria CO6300962A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1652207P 2007-12-24 2007-12-24
US1652507P 2007-12-24 2007-12-24

Publications (1)

Publication Number Publication Date
CO6300962A2 true CO6300962A2 (es) 2011-07-21

Family

ID=40560235

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10071043A CO6300962A2 (es) 2007-12-24 2010-06-11 Una proteina de fusion que comprende proteina circumesporozoito para uso en una vacuna contra la malaria

Country Status (21)

Country Link
US (1) US8999347B2 (es)
EP (1) EP2234638A1 (es)
JP (1) JP2011507817A (es)
KR (1) KR20100111281A (es)
CN (1) CN101951947A (es)
AP (1) AP2010005294A0 (es)
AR (1) AR069936A1 (es)
AU (1) AU2008339969A1 (es)
BR (1) BRPI0821531A2 (es)
CA (1) CA2709041A1 (es)
CL (1) CL2008003875A1 (es)
CO (1) CO6300962A2 (es)
CR (1) CR11585A (es)
DO (1) DOP2010000186A (es)
IL (1) IL206311A0 (es)
MA (1) MA32029B1 (es)
PE (1) PE20091529A1 (es)
TW (1) TW200940087A (es)
UY (1) UY31574A1 (es)
WO (1) WO2009080803A1 (es)
ZA (1) ZA201004414B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9364525B2 (en) * 2006-07-18 2016-06-14 Glaxosmithkline Biologicals Sa Vaccines for malaria
GB201022007D0 (en) 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
GB201608821D0 (en) 2016-05-19 2016-07-06 Isis Innovation Vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69228698T2 (de) * 1991-11-16 1999-09-16 Smithkline Beecham Biologicals S.A., Rixensart HYBRIDES PROTEIN ZWISCHEN CS AUS PLASMODIUM UND HBsAG
GB9616351D0 (en) 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
CA2593643C (en) * 2005-01-18 2016-03-22 Walter Reed Army Institute Of Research A plasmodium vivax hybrid circumsporozoite protein and vaccine
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US9364525B2 (en) * 2006-07-18 2016-06-14 Glaxosmithkline Biologicals Sa Vaccines for malaria

Also Published As

Publication number Publication date
IL206311A0 (en) 2010-12-30
EP2234638A1 (en) 2010-10-06
BRPI0821531A2 (pt) 2015-06-16
CL2008003875A1 (es) 2010-02-05
US8999347B2 (en) 2015-04-07
DOP2010000186A (es) 2010-09-30
AP2010005294A0 (en) 2010-06-30
CN101951947A (zh) 2011-01-19
CA2709041A1 (en) 2009-07-02
MA32029B1 (fr) 2011-01-03
AR069936A1 (es) 2010-03-03
JP2011507817A (ja) 2011-03-10
AU2008339969A1 (en) 2009-07-02
KR20100111281A (ko) 2010-10-14
WO2009080803A1 (en) 2009-07-02
UY31574A1 (es) 2009-08-03
US20100272788A1 (en) 2010-10-28
PE20091529A1 (es) 2009-10-29
CR11585A (es) 2010-09-03
TW200940087A (en) 2009-10-01
ZA201004414B (en) 2014-11-26

Similar Documents

Publication Publication Date Title
HRP20210608T1 (hr) Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
AR061894A1 (es) Vacunas para malaria
DK1951299T3 (da) Influenzavacciner indeholdende kombinationer af partikelformige adjuvanser og immunforstærkere
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
PE20140844A1 (es) Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
UA113049C2 (xx) Спосіб зберігання вакцини, яка містить ад'ювант на основі алюмінію
WO2013006842A3 (en) Self-replicating rna prime - protein boost vaccines
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
WO2013177214A3 (en) Epitope focusing by variable effective antigen surface concentration
WO2010104761A3 (en) Anti-cd40 antibodies and uses thereof
IN2014DN10288A (es)
EP4272750A3 (en) Protein antigens that provide protection against pneumococcal colonization and/or disease
EA201892735A1 (ru) Состав вакцины против hiv
EA202090699A3 (ru) Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
EA201590829A1 (ru) Новые мукозные адъюванты и системы доставки
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
AR080111A1 (es) Metodos y composiciones de inmunizacion
CO6300963A2 (es) Una vacuna contra la malaria que comprende p. falciparum y p. vivax
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
CO6561819A2 (es) Vectores para vacunas y método para potenciar respuestas inmunes
PE20240133A1 (es) Vacuna de nanoparticula a base de proteinas contra metapneumovirus
CO6300962A2 (es) Una proteina de fusion que comprende proteina circumesporozoito para uso en una vacuna contra la malaria

Legal Events

Date Code Title Description
FC Application refused